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ABSTRACT
Background: In 2014, the Joint United Nations
Programme on HIV and AIDS (UNAIDS) and partners
set the ‘90-90-90 targets’; aiming to diagnose 90% of
all HIV positive people, provide antiretroviral therapy
(ART) for 90% of those diagnosed and achieve viral
suppression for 90% of those treated, by 2020. This
results in 81% of all HIV positive people on treatment
and 73% of all HIV positive people achieving viral
suppression. We aimed to analyse how effective
national HIV treatment programmes are at meeting
these targets, using HIV care continuums or cascades.
Methods: We searched for HIV treatment cascades for
196 countries in published papers, conference
presentations, UNAIDS databases and national reports.
Cascades were constructed using reliable,
generalisable, recent data from national, cross-sectional
and longitudinal study cohorts. Data were collected for
four stages; total HIV positive people, diagnosed, on
treatment and virally suppressed. The cascades were
categorised as complete (four stages) or partial (3
stages), and analysed for ‘break points’ defined as a
drop >10% in coverage between consecutive 90-90-90
targets.
Results: 69 country cascades were analysed
(32 complete, 37 partial). Diagnosis (target one
—90%) ranged from 87% (the Netherlands) to 11%
(Yemen). Treatment coverage (target two—81% on
ART) ranged from 71% (Switzerland) to 3%
(Afghanistan). Viral suppression (target three—73%
virally suppressed) was between 68% (Switzerland)
and 7% (China).
Conclusions: No country analysed met the 90-90-90
targets. Diagnosis was the greatest break point globally,
but the most frequent key break point for individual
countries was providing ART to those diagnosed. Large
disparities were identified between countries. Without
commitment to standardised reporting methodologies,
international comparisons are complex.
BACKGROUND
In 2014, the Joint United Nations
Programme on HIV and AIDS (UNAIDS)
and partners launched three ambitious
90-90-90 targets for 2020 as a commitment to
improve access to antiretroviral therapy
(ART)1 as a life-saving treatment,1 2 a trans-
mission prevention measure3 and a human
right.4 These three targets are as follows:
target one is successfully diagnosing 90% of
all HIV positive people. Target two involves
delivering antiretroviral therapy (ART) to
90% of those diagnosed, and ﬁnally, target
Key questions
What is already known about this topic?
▸ Cascades of HIV care have been used for a few
years by national treatment programmes to
depict the effectiveness of coverage of care. For
most countries, where cascade reports have
been published annually, progress has been
seen.
▸ The Joint United Nations Programme on HIV
and AIDS (UNAIDS) calls for countries to
improve diagnosis of HIV, access to antiretroviral
therapy (ART) and achievement of viral suppres-
sion with the 90-90-90 targets.
What are the new findings?
▸ Cascade reporting methods are relatively hetero-
geneous; however, with the new UNAIDS
90-90-90 targets, WHO treatment guidelines and
reporting indicator requirements, more and
more countries should begin to report cascades
more uniformly.
▸ Large disparities exist between countries. While
some are close to meeting the UNAIDS 2020
goals already, others will require a great deal of
progress over the coming years.
Recommendations for policy
▸ Countries should be clear and precise when
reporting the stages of a cascade, so that pro-
gress can be monitored as we move towards
2020 and resources can be targeted towards the
stages in the cascade, where the most attrition
occurs.
▸ This research was constructed using the most
recent publicly available data as of September
2015. We would warmly welcome any more
recent or more reliable national-level data, from all
countries not yet included, or updates to the 69
included countries, for a follow-up to this project.
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three involves achieving viral suppression for 90% of
those on treatment. This ﬁnal goal of projected cover-
age, allowing for serial 10% losses at each subsequent
step, results in 73% of all HIV positive individuals achiev-
ing viral suppression.1
Effective and safe delivery of medical care for HIV
requires a sequence of diagnostic tests, assessments, treat-
ment delivery, support and monitoring. This care con-
tinuum has been termed the ‘HIV treatment cascade’.
The cascade can be used to illustrate and measure the
effectiveness of a country’s ART programme.5 Cascades
report various stages, including total HIV positive people,
diagnosed, linked to care, retained in care, treatment eli-
gibility, on ART, adherence to treatment, retention post
ART initiation and viral suppression. Following the
results of, Strategic Timing of Antiretroviral Treatment
(START),2 TEMPRANO6 and recent WHO guidelines7
shifting towards ‘treating all diagnosed positive’, CD4 eli-
gibility should no longer be relevant.
Several key factors affect coverage of the various steps
of HIV cascades; individual, societal and structural.8
Initially, community education and uptake of testing is
required at a population level, widespread among gener-
alised epidemics and targeted testing within focused epi-
demics. Second, linkage to care, retention in care and
support following diagnosis is required for all HIV posi-
tive individuals prior to starting treatment. Sustainable
procurement and provision of ART is imperative. Finally,
individual understanding and motivation is required to
maintain treatment adherence9 and post ART retention
combined with HIV viral load testing for monitoring.
Until recently, there has been an absence of standar-
dised reporting methodologies, stage deﬁnitions and
agreed structures to unify cascade data, making compari-
son of HIV treatment cascades difﬁcult.10 UNAIDS has
recently issued 10 national-level indicators for HIV report-
ing to unify the reporting process.7 11 This study aims to
provide national-level cascade data using currently avail-
able ﬁgures so that progress can be monitored on the way
to 2020, as better reporting systems are implemented.
METHODS
Global cascade construction method
UNAIDS11 estimates that in 2014 there were 36.9 million
people living with HIV. Applying the 90-90-90 percen-
tages to this ﬁgure shows how many people should be in
each cascade stage. The gaps in each stage were esti-
mated using published ﬁgures for the total number of
people diagnosed and on ART globally, in 2014.11 A sys-
tematic review on viral suppression rates in low and
middle-income countries was used to estimate the total
number of individuals with a supressed viral load at
12 months on intention to treat analysis.12
HIV treatment cascade selection and inclusion criteria
We searched OvidSP, PubMed, UNAIDS databases and
national reports for HIV treatment cascades published
up to August 2015. Search terms were ‘HIV’ or ‘AIDS’
and ‘treatment cascade’ or ‘continuum of care’ separ-
ately combined with 196 individual country names (ﬂow
diagram online supplementary appendix ﬁgure 1).
In order to evaluate the 90-90-90 targets, data were
extracted for four main stages; 1—total number of HIV
positive people; 2—number of people diagnosed; 3—
number of people on treatment; 4—number of people
achieving viral suppression. Viral suppression was often
listed as ‘undetectable HIV RNA’, ranging from <1000
copies HIV RNA/mL to <40 copies HIV RNA/mL
depending on test sensitivity, but sometimes the cut-off
used was not reported (NA).
Complete cascades were deﬁned as those which
reported numbers and percentages for all four of these
stages. Partial cascades reported numbers or percentages
for three of these stages. We excluded cascades which
reported fewer stages and excluded data from smaller
cohorts (eg, regional data from British Columbia)13 or
non-generalisable groups (eg, research studies)14 15 or
cascades exclusively from high-risk groups (eg, female
sex workers16 (FSW) or men who have sex with men16 17
(MSM)).
Data sets were generated based on either longitudinal
(individual-level data followed within a cohort study) or
cross-sectional studies (national surveillance studies).
Some cascades were constructed from a combination of
representative longitudinal studies, which were projected
onto cross-sectional sources (combination method).
National cascade stage definitions
Data for many countries were extracted from UN
General Assembly Special Session (UNGASS) country-
level reports, submitted to UNAIDS using the Global
AIDS Response Progress Reports tool (GARPR).17 A
short overview of the data collection methods reported
for each of the four main stages are outlined below:
1. Total HIV positive population. Estimates of the total
HIV epidemic size were generally calculated using
Spectrum17 or back calculated using other epidemio-
logical models based on data from national HIV
testing programmes or smaller anonymous unlinked
seroprevalence surveys.18–21
2. Number diagnosed as HIV positive. The number of
people diagnosed was deﬁned using country reports
of the cumulative number of people tested and
found HIV-1 positive.16 Diagnosis was made using
HIV antibody tests minus false positives, those
recorded to have died or permanently migrated17
(eg, the Netherlands22). Testing procedures differed
between countries where some require two or more
HIV positive tests to conﬁrm diagnosis (eg,
Uganda17).
Despite linkage and retention in care being extremely
important components of the care continuum for
country-level monitoring and individual patients, these
stages were not analysed for break points because there
are not corresponding targets within the 90-90-90 goals
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(available in the online supplementary appendix ﬁgures
2.01–2.69). Deﬁnitions of linkage and retention are
highly heterogeneous between cascades, making com-
parison across countries difﬁcult.10 Some countries
report pre ART eligibility23 based on CD4 count, but as
national guidelines vary greatly between countries and
WHO guidelines shift towards treatment irrespective of
CD4 count,7 this stage was excluded.
3. Number on ART. ART coverage was generally calcu-
lated using records of drugs dispensed from health-
care facilities, pharmacy records and governmental
drug purchases (adjusted for treatment change, pre-
exposure and postexposure prophylaxis use). Our
analysis did not differentiate between different ART
regimens prescribed, as most countries did not break
this down. Initiation on ART constituted this category
despite many countries also reporting 6-month and
12-month post ART retention. Countries without a
centralised national dispensary or with many private
or non-government organisation (NGO) treatment
providers may underestimate the number of people
on ART unless this dispensary data are collated. The
USA, for example, attempts to overcome this
problem collating data in the medical monitoring
project and centre for disease control.17
4. Viral suppression. The threshold for undetectable
HIV RNA ranged from <40 copies/mL (Rwanda,24
Tanzania17) to <1000 copies/mL (Russia23). We
included data where at least one viral load measure
was recorded <1000 following treatment. Intention to
treat analysis at 12 months was preferred if multiple
ﬁgures were reported.12 25 For countries where viral
load measurements are not routine, estimates were
extrapolated from smaller generalisable cohorts (eg,
Uganda17). Adherence, high CD4 counts (eg, Italy26)
or post ART retention were not accepted as surrogate
markers for viral suppression. Viral suppression was
estimated for 10 African countries (Nigeria, Zambia,
Zimbabwe, Senegal, Cote d’Ivoire, Burkina Faso,
Mozambique, Cameroon, Tanzania and Botswana)
where national reports11 did not indicate viral sup-
pression rates. We applied the percentages from a sys-
tematic review25 (also used by UNAIDS to estimate
the average viral suppression rates for sub-Saharan
Africa11) to these individual countries following post
ART retention at 12 months.
Break point definition
The 90-90-90 targets permit a drop by 10% between
each of the four stages of the cascade11 (see table 1).
We deﬁned a reduction in coverage by >10% between
any of the three 90-90-90 targets as a ‘break point’ in the
cascade. We deﬁned the greatest percentage drop for
each cascade as the ‘key break point’ for that country, so
that they can identify their main area of attrition.
Break point analysis was calculated for each country by
plotting the percentage of people retained for target
one versus target two and also for target two versus
target three. As so few countries yet meet the 90%
targets, we separated these graphs into four quadrants
using cut-offs of 65% to allow countries to see what
targets to focus on. A similar method was used in a
recent cascades analyse (with a 60% cut-off), which
modelled potential reductions in incidence if the
90-90-90 targets were to be met.27
FINDINGS
Global estimates
Figure 1A summarises the 90-90-90 targets and ﬁgure 1B
illustrates the estimated number of people currently in
each stage worldwide. Globally, of all HIV positive
people, an estimated 54% were diagnosed,11 41% were
on ART11 and 32% were estimated to achieve viral sup-
pression.11 12 This means that globally, break points are
54% at diagnosis, 76% of those diagnosed are on treat-
ment and 78% of those on treatment achieve viral sup-
pression. The gaps illustrate that 13.4 million more
people need to be diagnosed, we have to double the
number currently on ART and a further 15.3 million
people and to achieve undetectable HIV RNA in order
to reach these targets. Furthermore, the numbers of
people diagnosed, on treatment and suppressed may be
overestimated, due to sampling bias or incomplete
reporting, as well as migration; making it difﬁcult to
track of many HIV positive people.
National cascade analysis
Of the 196 countries searched, data were found for 69
countries (32 complete, 37 partial), outlined in online
supplementary table S1. Detailed summaries of all
country data and deﬁnitions used are presented in the
Table 1 UNAIDS 90-90-90 target definitions.
Percentage
of All HIV
positive
people
90-90-90
Target
Calculation
method
Target
one
90 90% of all
HIV positive
people
diagnosed
Numerator=Total
number of people
diagnosed.
Denominator=Total
number of HIV
positive people
Target
two
81 90% of those
diagnosed
on
antiretroviral
therapy
(ART)
Numerator=Total
number of people
on ART
Denominator=Total
number of people
diagnosed
Target
three
73 90% of those
on ART
achieving
viral
suppression
Numerator=Total
number of people
virally suppressed
Denominator=total
number of people
on ART
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supplementary appendix ﬁgures 2.01–2.69, cascade data
were either incomplete or excluded for 127 countries.
Figure 2Ai, Aii shows a comparison across 32 countries
with full cascades and 23 countries with partial cascades,
where data were available for target one, that is, diagno-
sis. While no country reached the 90% target for HIV
diagnosis, there is a wide range from 87% (the
Netherlands and Estonia) to 11% (Yemen).
Figure 2Bi, Bii compares results for 32 countries with
full cascades and 34 countries with partial cascades,
where data were available for target two, that is, treat-
ment coverage. No country reached the overall 81%
target for ART coverage. Results ranged from 71%
(Switzerland) to 3% (Afghanistan and Yemen).
Figure 2Ci, Cii compares results for target three for 32
countries with full cascades and 12 countries with partial
cascades respectively, where data were available for
target three, that is, viral suppression. Viral load thresh-
old used varied from <40 (Rwanda, Tanzania) to <1000
(Russia, Uganda, Kenya, Belarus, Mauritius, Nepal, Lao,
Columbia, Mongolia and China) HIV RNA copies/mL.
No country reached the overall target for viral suppres-
sion of 73% of all HIV positive people. The range of
virally suppressed individuals is from 68% (Switzerland)
to 7% (China).
Figure 3A illustrates the break points for 53 countries
with available data for targets one and two. Break points
are drawn at the 90% mark, and these ﬁgures are sepa-
rated into four quadrants. Countries that are the closest
to targets one and two are clustered in the upper right
quadrant of the graph. The UK is the only country to
meet target two (with 76% diagnosed, 90% of those
diagnosed receive treatment) followed by Switzerland
(81% and 88%, respectively). Countries in the upper
left quadrant are doing well at testing but need to focus
on proving ART to those diagnosed. Those in the lower
right quadrant are doing poorly at testing but are doing
well at treating those diagnosed, for example, Mongolia
diagnosed 23% but 78% of those received treatment
with similar ﬁndings for Morocco (35% and 75%,
respectively). The furthest countries from achieving
target one and two are in the lower left quadrant, for
example, Afghanistan (31% diagnosed and 11% of
those diagnosed on treatment), Iran (30% and 24%,
respectively) and Yemen (11% and 24%, respectively).
Figure 3B compares 35 countries with available data
for targets two and three. Countries closest to these
targets are clustered towards the top of the upper right
quadrant. Seven countries meet or exceed target three
with over 90% of those on treatment achieving viral sup-
pression (Austria, Belgium, Denmark, the Netherlands,
Australia, Switzerland and the UK). Countries in the
lower right quadrant still perform relatively well at pro-
viding ART to those diagnosed, but fail to achieve viral
suppression for those on treatment, for example,
Venezuela (70% of those diagnosed received ART and
31% of those on treatment achieved viral suppression).
Countries in the upper left quadrant performed poorly
at diagnosis, but maintained relatively good viral sup-
pression rates for those on treatment. The countries fur-
thest from achieving targets two and three are in the
lower left quadrant of the graph, where diagnosis rates
and viral suppression rates are low, for example, China
(43% and 36%, respectively) and Nicaragua (38% and
39%, respectively).
DISCUSSION
Wide disparities were observed between HIV treatment
cascades for the 69 countries evaluated. As anticipated,
we encountered multiple discrepancies in the method-
ologies and reporting systems used by each country,
which limits the overall ﬁndings discussed below.
However, this analysis provides novel and important
insight into where the main gaps in the cascade are for
each country. Large randomised community trial results
show 90-90-90 targets are achievable with planning, polit-
ical will and funding.14 28 To allow accurate compari-
sons, standardised and continuous global monitoring of
HIV care outputs should become a priority.10
Diagnosis
Results for target one depend greatly on several factors
such as the total epidemic size estimation method,
testing technology, data collection method and model-
ling of errors. With improved epidemic modelling tools
such as Spectrum being widely used, this will become
Figure 1 Compares the UNAIDS targets for 2020 with global
estimates for 2014/15.
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more uniform.17 To enhance reliability, some countries
use anonymous seroprevalence surveys (eg, UK19) in
generalised cohorts. Diagnosis reporting, requires
unique patient identities which is not always feasible in
many settings meaning double counting may occur.17
Countries with high diagnosis rates were mostly
high-income European or South American. Multiple
factors inﬂuence the uptake of HIV testing coverage29
and these can be categorised as individual,30 struc-
tural6 9 (eg, healthcare system capacity) and societal
barriers (eg, stigma31). HIV testing kits are cheap and
many countries test for free,17 but encouraging HIV
testing behaviour in high-risk communities is challen-
ging.28 Furthermore, to achieve signiﬁcant and sus-
tained impact on the epidemic, encouraging repeat
HIV testing is necessary.32 33 Interventions to improve
diagnosis include educational and behavioural pro-
grammes and campaigns to reduce discrimination.31
To address the signiﬁcant shortfall at diagnosis in
resource-limited settings, innovative approaches to
increase testing coverage have been explored. These
include partner testing,34 community-based interven-
tions (eg, TasP,14 PopART28 and SEARCH trials14),
opt-out testing,34 self-testing35 and work-based or
Figure 2 A(i) Percentage of
total HIV positive people receiving
diagnosis for 32 countries with full
cascades. A(ii) Percentage of
total HIV positive people receiving
diagnosis for 23 countries with
partial cascades. B(i) Percentage
of total HIV positive people
receiving ART for 32 countries
with full cascades. B(ii)
Percentage of total HIV positive
people receiving ART for 34
countries with partial cascades. C
(i) Percentage of total HIV
positive people achieving
undetectable HIV RNA for 32
countries with full cascades. C(ii)
Percentage of total HIV positive
people achieving undetectable
HIV RNA for 12 countries with
partial cascades.
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home-based community testing (HBCT)36 which was
shown to reach up to 80% coverage of testing in high-
burden countries, but may not be cost-effective in low-
prevalence countries. Cost-effectiveness modelling has
shown that HBCT will improve diagnosis but will not
be enough without strong linkage and ART coverage,
and ‘front-loading’ may be required to optimise
efﬁciency.37
Treatment
The wide diversity observed between countries for the
number of people ‘on ART’ in the cascade is multifac-
torial including; sociocultural determinants,38 structural
barriers,9 costs of services and medicines,39 healthcare
facility capacities9 and drug availability stock-outs.32
Countries where the greatest break point was at ART
provision to those diagnosed, and countries in the
Figure 2 Continued
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upper and lower left quadrants of ﬁgure 3B need to
develop creative strategies to link, retain and treat those
diagnosed. The RapIT study found, immediate or same
day ART initiation following diagnosis is very effective in
low-resource settings.40
Linkage to care, retention in healthcare systems34 and
eligibility for ART (as directed by national guidelines)
impact the step from diagnosis to successful treatment.41
However, due to lack of consistency in deﬁnitions across
countries, these steps between testing and ART initiation
are not possible to accurately compare due to hetero-
geneity. For example, in Russia23 ‘linkage’ was consti-
tuted by ‘one visit to an AIDS centre within 12 months
of diagnosis’. Contrastingly, in the USA, linkage was
deﬁned more stringently as ‘one CD4 test performed
within 3 months of diagnoses.18’ The number of people
‘on ART’ is also an imprecise value, even if calculated
from prescription records, not everyone prescribed ART
Figure 3 (A) Target 1 vs Target 2 - % of those diagnosed vs % of those diagnosed receiving ART. (B) Target 2 vs Target 3 - %
of those diagnosed on ART vs % of those on ART achieving viral suppression.
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actually receives or adheres to it. Adherence, a common
factor in treatment failure,9 was rarely reported
(eg, France, 60%20) and was inconsistently deﬁned,
therefore, we did not compare countries at this stage.
Viral suppression or post ART retention are more
important ﬁnal markers for successful treatment26 as
prevention of viral transmission3 42 and to reduced mor-
bidity and mortality.2
Healthcare system differences may impact ART cover-
age, in particular public versus private provision of treat-
ment.38 Financial constraints were barriers in Australia
where copayments were required and treatment was not
free for all (such as migrants).43 Task shifting,44 where
specially trained non-medical staff initiates ART, has
helped improve ART coverage challenges in some
resource-limited settings.45 This can decongest clinical
facilities when healthcare facility capacity is constrained.
Our analysis is limited as country data range from 2010
to 2014, and some countries have experienced monu-
mental coverage increases over this period.11 However,
this is promising news for the countries struggling to
reach target two and for the global community aiming
to reach the 90-90-90 targets by 2020.
Viral suppression
Of the 32 full cascades analysed that reported viral sup-
pression data, all achieved undetectable HIV RNA for
over 50% of people receiving ART, except for China,
Nicaragua and Venezuela. Sustained maintenance of
viral suppression is not always reﬂected here, because
cross-sectional studies may only report one viral load
measurement. Not all countries reported data for viral
suppression and many reﬂected ‘on treatment’ analysis
and cannot account for those lost to follow-up. For the
10 African countries, where viral suppression was esti-
mated from combining country-level reports11 with a sys-
tematic review,25 these results may not represent the true
levels due to selection bias in the studies. The deﬁnition
of undetectable HIV RNA varied from <50 RNA copies/
mL (eg, France20) to <1000 RNA copies/mL (eg,
Russia23). Brazil has 35% (255 000) of HIV positive
people achieving undetectable HIV RNA using the <50
RNA copies/mL deﬁnition; however, if the <1000
copies/mL deﬁnition was used, this would rise to 40%
(293 000).46
Age, ethnicity and socioeconomic status are associated
with percentage achieving undetectable HIV RNA in the
USA, possibly reﬂecting healthcare funding.47 Structural
barriers impact viral suppression. In low and
middle-income countries, barriers to treatment reten-
tion, drug stock-outs and loss to follow-up remain obsta-
cles for successful outcomes.9 Simpliﬁcation of
treatment to single ﬁxed-dose combinations, community
delivery of therapy, simpliﬁcation of pathways to repeat
prescriptions48 and adherence clubs may all enhance
treatment effectiveness.
Variation within country cascades
Most of the cascades analysed in this study were cumula-
tive cross sectional or were longitudinal and cross-
sectional analysis combined. Cross-sectional studies are
simpler and cheaper for large populations; however, par-
ticipants may exit and return at various stages, meaning
they could be counted twice or not be counted at all
within the time frame of data collection. Longitudinal
studies track patients continuously and allow relatively
fewer points where patients may be lost to follow-up and
facilitate assessment of annual changes. Countries closest
to approaching the 90-90-90 goals, in the upper right
quadrants in ﬁgure 3A, B, are generally high-income, low-
prevalence, except for Rwanda,24 Thailand49 and
Zimbabwe.17 25 Other high-burden, lower-income coun-
tries could learn from their systems and successes.
CONCLUSION
Of the 69 countries included in this analysis, none cur-
rently meet the three 90-90-90 targets. The ‘key break
point’ globally is HIV diagnosis, whereas the most
common break point for the countries analysed here
was between diagnosis and provision of ART. Multiple
factors inﬂuence the success of the HIV treatment
cascade such as epidemic stage, population demogra-
phics, healthcare systems, treatment costs and policy and
treatment guidelines. In order to develop better
methods to analyse and compare cascades, standardised
reporting tools, better monitoring and timely reporting
are required.
Note to all readers:
This research was constructed using the most recent
publicly available data as of September 2015. We would
warmly welcome any more recent or more reliable
national-level data, from all countries not yet included,
or updates to the 69 included countries, for a follow-up
to this project.
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